相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名:
Pelargonic acid vanillylamide; Nonanoic acid vanillylamide; Pseudocapsaicin
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
2444-46-4
- 规格:
10 mM * 1 mL/100 mg/500 mg/1 g/5 g
| 规格: | 10 mM * 1 mL | 产品价格: | ¥275.0 |
|---|---|---|---|
| 规格: | 100 mg | 产品价格: | ¥250.0 |
| 规格: | 500 mg | 产品价格: | ¥450.0 |
| 规格: | 1 g | 产品价格: | ¥600.0 |
| 规格: | 5 g | 产品价格: | ¥840.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Nonivamide
CAS No. : 2444-46-4
MCE 国际站:Nonivamide
产品活性:Nonivamide 是一种
研究领域:Membrane Transporter/Ion Channel | Neuronal Signaling
作用靶点:TRP Channel
In Vitro: Nonivamide, a synthetic derivate of natural capsaicin, has an effective antifouling activity. Capsaicin exhibits 4d-EC50 values of 5.5±0.5 mg/L, 23±2 mg/L, 6.9±0.2 mg/L, and 15.6±0.4 mg/L in static toxicity tests conducted using Pseudomonas putida, Lake Erie bacteria, Vibrio natriegens, and Vibrio parahaemolyticus, respectively. A significant growth inhibitory effect (p<0.01) is observed in the group treated with 1 mg/L of Nonivamide for 4 d, and the EC50 value (4 d-EC50) is 5.1 mg/L. Nonivamide treatment causes calcium release from the ER and altered the transcription of growth arrest- and DNA damage-inducible transcript 3 (GADD153), GADD45α, GRP78/BiP, ATF3, CCND1, and CCNG2) in a manner comparable with prototypical ER stress-inducing agents. ER calcium flux is evaluated by pretreating cells with 2.5 μM thapsigargin for 5 min followed by addition of 2.5 μM Nonivamide. Treatment of TRPV1-overexpressing cells with 2.5 μM Nonivamide produces marked increases in cytosolic calcium due to release of calcium from ER stores. Treatment of TRPV1-overexpressing cells with 1 μM Nonivamide causes an approximate 50% loss in cell viability after a 24-h period. BEAS-2B cells treated with 100 and 200 μM Nonivamide also exhibits a shift in the relative amount of EIF2α-P and an increase in the expression of GADD153 mRNA and protein. Treatment with Nonivamide reduces lipid accumulation to a similar extent as CAP; the effects are not different from the effects after CAP treatment at any of the tested concentrations. Compared to untreated control cells, treatment with Nonivamide decreases lipid accumulation by 5.34±1.03% (P<0.05) at 0.01 µM up to 10.4±2.47% (P<0.001) at 1 µM.
相关产品:Natural Product Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Membrane Transporter/Ion Channel Compound Library | Neuronal Signaling Compound Library | Natural Product Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | Lipid Compound Library | Endoplasmic Reticulum Stress Compound Library | Phenols Library | Traditional Chinese Medicine Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Alkaloids Library | Food Additive Library | Food-Sourced Compound Library | Mechanoreceptors Compound Library | Plant-Sourced Natural Product Library | Human Metabolite Library | Non-steroidal Anti-Inflammatory Compound Library | Pain-Related Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | FDA-Approved Traditional Chinese Medicine Active Compound Library | Ion Channel Compound Library | Rosiglitazone | Capsaicin | GsMTx4 | EIPA | Probenecid | Diphenyleneiodonium chloride | 2-Aminoethyl diphenylborinate | Amiloride hydrochloride | GSK1016790A | Capsazepine | HC-067047 | HC-030031 | ML-SA1 | GSK2193874 | Adenosine 5′-diphosphoribose sodium | AMG9810 | GSK205 | SKF-96365 hydrochloride | (-)-Menthol | Caffeic acid | ML-SI1 | BI-749327 | GSK2798745 | Pregnenolone | ML-SA5 | N-(p-amylcinnamoyl) Anthranilic Acid | A-967079 | MK6-83 | Pico145
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验.5 96 4.2 汽巴康宁 2 46 4.89 24 2.08 19.3 -5.76
汽巴康宁2 46 4.89 24 2.08 19.3 -5.76 184 -11.7 265 0.2
% 鲍曼不动杆菌 89 4.46% 革兰阳性芽胞杆菌 69 3.46
技术资料暂无技术资料 索取技术资料

















